For ER+ advanced breast cancer patients, the randomized clinical trial CAPItello-291 showed the added benefit of the Akt inhibitor Capivasertib in combination with Fulvestrant38, presenting a possible treatment regime for early stage ER+ BC patients. Here, AKT1 is linked to breast carcinoma.